Amarin announces senior management changes
Connecticut firm appoints ceo, president and principal accountant
Zakrzewski has more than 20 years of experience, including holding the position of chief operating officer of Reliant Pharmaceuticals when Omacor/Lovaza was developed and acquired in 2007 by GlaxoSmithKline. He was most recently chief executive of Xcellerex, a Massachusetts-based biotechnology company. Although he currently serves on the boards of directors and in other advisory roles for various companies, Amarin is his primary business commitment.
Additionally, John Thero has been promoted to Amarin’s president. Since November 2009, he has been the company’s chief financial officer.
Prior to joining Amarin, Thero was chief financial officer at ViaCell, where he helped guide the sale of the company, and Abiomed, during its transition from a development-stage company into a commercial entity.
Colin Stewart, who was Amarin’s president and ceo, resigned last month to address personal matters.
In connection with these changes, Frederick Ahlholm, vice president finance, has become the company’s principal accounting officer.
You may also like
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Neuland Laboratories announces new $20m process development lab in Hyderabad]()
Neuland Laboratories announces new $20m process development lab in Hyderabad
The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs
Regulatory
![FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs]()
FDA approves Utebzi, first oral carbapenem antibiotic, for complicated UTIs
GSK and Spero Therapeutics' tebipenem pivoxil matches IV imipenem-cilastatin in Phase III trials, offering an outpatient alternative for resistant infections that cost the US healthcare system more than $6bn annually
Pharmaceutical
![Maximising product recovery with a GFD filter dryer removable basket]()
Maximising product recovery with a GFD filter dryer removable basket
Product value is often inversely proportional to volume in pharmaceutical R&D and kilo-lab production. When synthesising a few hundred grams of a novel drug candidate, every milligram can represent weeks of experimentation, costly reagents, and the potential success of a clinical trial
Pharmaceutical
![How pressure and vacuum filtration in ANFDs improves yield]()
How pressure and vacuum filtration in ANFDs improves yield
During solid-liquid separation in industries such as pharmaceuticals and fine chemicals, both process efficiency and product quality are critical requirements. Effective use of pressure and vacuum filtration can help address this in downstream processing
